07.14.15
Headquarters: New Brunswick, NJ
twitter.com/JNJComm
www.jnj.com
TOP SELLING DRUGS
Worldwide pharmaceutical sales of $32.3 billion for the full-year 2014 represented an increase of nearly 15% versus the prior year for J&J. Domestic sales increased 25%, while international sales grew 5%.
J&J’s rather strong sales results were driven by new products and the strength of core product performance. New products launched during the year include Olysio/Sovriad (simeprevir), for combination treatment of chronic hepatitis C in adult patients; Xarelto (rivaroxaban), an oral anticoagulant; Zytiga (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer; Invokana (canagliflozin), for the treatment of adults with type 2 diabetes; and Imbruvica (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, or blood cancers.
During the year J&J acquired Alios BioPharma, Inc., a clinical stage biopharma company focused on therapies for viral diseases, for approximately $1.75 billion. Alios’ lead candidate AL-8176 is an orally administered antiviral therapy currently in Phase II development for the treatment of infants with respiratory syncytial virus (RSV).
In January, J&J divested the U.S. license rights to Nucynta (tapentadol), Nucynta ER extended-release tablets, and Nucynta oral solution for approximately $1.05 billion to Depomed.
Collaboration is key
Janssen, the pharmaceutical companies of J&J, entered several strategic collaborations during the year, as well as announcing the formation of Janssen Global Public Health (Janssen GPH), a new group that will be responsible for clinical and product development and creating and implementing new strategies for its portfolio of pharmaceuticals, diagnostics, and services for diseases impacting resource-limited countries and emerging markets.
Halozyme Therapeutics entered into a worldwide collaboration and license agreement with Janssen Biotech to develop and commercialize products combining Janssen compounds with Halozyme’s Enhanze technology. Enhanze is based on a recombinant human hyaluronidase enzyme (rHuPH20) that temporarily modifies hyaluronan to aid in the dispersion and absorption of other injected drugs.
Transposagen Biopharmaceuticals entered into a research and worldwide license agreement with Janssen to develop allogeneic Chimeric Antigen Receptor T-cells (CAR-T). CAR-T therapies have shown promise in early trials for the treatment of blood cancers and have the potential for use as off-the-shelf cancer treatments without the need of matching donor with recipient.
Aduro BioTech entered into its second agreement with Janssen granting an exclusive, worldwide license to certain product candidates for the treatment of lung cancer and certain other cancers, based on its LADD immunotherapy platform.
Bristol-Myers Squibb, Pharmacyclics and Janssen R&D all entered a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of BMS’ investigational PD-1 immune checkpoint inhibitor OPDIVO (nivolumab) in combination with Imbruvica (ibrutinib), an oral Bruton’s tyrosine kinase (BTK) inhibitor co-developed and co-marketed by Pharmacyclics and Janssen.
Janssen Pharmaceuticals also formed a collaboration with Vertex Pharmaceuticals on worldwide development, manufacturing and commercialization of VX-787, an investigational medicine now in Phase II development for the treatment of influenza A.
Janssen R&D Ireland entered a collaboration with ViiV Healthcare to develop and commercialize a new single tablet regimen containing Janssen’s Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine (Edurant) and ViiV’s Integrase Inhibitor dolutegravir (TIVICAY), as the sole active ingredients for the maintenance treatment of HIV. The companies will also investigate development of the drug combination for pediatric use.
Novozymes Biopharma entered a collaboration with Janssen R&D under which Janssen will evaluate Novozymes’s engineered albumin-based Veltis technology for potential drug candidates.
twitter.com/JNJComm
www.jnj.com
Headcount: | 127,000 | |
Year Established: | 1887 | |
Revenues: | $74,331 | (+4%) |
Pharma Revenues: | $32,313 | (+15%) |
Net Income: | $16,323 | (+18%) |
R&D: | $6,213 | (+6%) |
TOP SELLING DRUGS
Drug | Indication | 2014 Sales | (+/-%) |
Remicade | rheumatoid arthritis | $6,868 | 3% |
Olysio/Sovriad | hepatitis C | $2,302 | n/a |
Zytiga | prostate cancer | $2,237 | 32% |
Stelara | psoriasis | $2,072 | 38% |
Prezista | HIV/AIDS | $1,831 | 9% |
Velcade | velcade, mantle cell lymphoma | $1,618 | -3% |
Invega Sustenna | schizophrenia | $1,588 | 27% |
Xarelto |
deep vein thrombosis, pulmonary embolism |
$1,522 | 76% |
Procrit | anemia | $1,238 | -9% |
Risperdal Consta | schizophrenia | $1,190 | -10% |
Simponi | rheumatoid arthritis | $1,187 | 27% |
Worldwide pharmaceutical sales of $32.3 billion for the full-year 2014 represented an increase of nearly 15% versus the prior year for J&J. Domestic sales increased 25%, while international sales grew 5%.
J&J’s rather strong sales results were driven by new products and the strength of core product performance. New products launched during the year include Olysio/Sovriad (simeprevir), for combination treatment of chronic hepatitis C in adult patients; Xarelto (rivaroxaban), an oral anticoagulant; Zytiga (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer; Invokana (canagliflozin), for the treatment of adults with type 2 diabetes; and Imbruvica (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, or blood cancers.
During the year J&J acquired Alios BioPharma, Inc., a clinical stage biopharma company focused on therapies for viral diseases, for approximately $1.75 billion. Alios’ lead candidate AL-8176 is an orally administered antiviral therapy currently in Phase II development for the treatment of infants with respiratory syncytial virus (RSV).
In January, J&J divested the U.S. license rights to Nucynta (tapentadol), Nucynta ER extended-release tablets, and Nucynta oral solution for approximately $1.05 billion to Depomed.
Collaboration is key
Janssen, the pharmaceutical companies of J&J, entered several strategic collaborations during the year, as well as announcing the formation of Janssen Global Public Health (Janssen GPH), a new group that will be responsible for clinical and product development and creating and implementing new strategies for its portfolio of pharmaceuticals, diagnostics, and services for diseases impacting resource-limited countries and emerging markets.
Halozyme Therapeutics entered into a worldwide collaboration and license agreement with Janssen Biotech to develop and commercialize products combining Janssen compounds with Halozyme’s Enhanze technology. Enhanze is based on a recombinant human hyaluronidase enzyme (rHuPH20) that temporarily modifies hyaluronan to aid in the dispersion and absorption of other injected drugs.
Transposagen Biopharmaceuticals entered into a research and worldwide license agreement with Janssen to develop allogeneic Chimeric Antigen Receptor T-cells (CAR-T). CAR-T therapies have shown promise in early trials for the treatment of blood cancers and have the potential for use as off-the-shelf cancer treatments without the need of matching donor with recipient.
Aduro BioTech entered into its second agreement with Janssen granting an exclusive, worldwide license to certain product candidates for the treatment of lung cancer and certain other cancers, based on its LADD immunotherapy platform.
Bristol-Myers Squibb, Pharmacyclics and Janssen R&D all entered a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of BMS’ investigational PD-1 immune checkpoint inhibitor OPDIVO (nivolumab) in combination with Imbruvica (ibrutinib), an oral Bruton’s tyrosine kinase (BTK) inhibitor co-developed and co-marketed by Pharmacyclics and Janssen.
Janssen Pharmaceuticals also formed a collaboration with Vertex Pharmaceuticals on worldwide development, manufacturing and commercialization of VX-787, an investigational medicine now in Phase II development for the treatment of influenza A.
Janssen R&D Ireland entered a collaboration with ViiV Healthcare to develop and commercialize a new single tablet regimen containing Janssen’s Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine (Edurant) and ViiV’s Integrase Inhibitor dolutegravir (TIVICAY), as the sole active ingredients for the maintenance treatment of HIV. The companies will also investigate development of the drug combination for pediatric use.
Novozymes Biopharma entered a collaboration with Janssen R&D under which Janssen will evaluate Novozymes’s engineered albumin-based Veltis technology for potential drug candidates.
J&J has swapped places with GSK this year as a result of some highly lucrative drug launches. The company is openly touting its drug pipeline announcing intentions to have 10 new drug launches by 2019 and expecting each of them to net $1 billion, while adding 40 line extensions. Making it big in vaccines, neuroscience, immunology, infectious diseases and CV/metabolism, and oncology is J&J’s aim. Indeed the pipeline does look strong with daratumumab for multiple myeloma, sirukumab for rheumatoid arthritis and guselkumab for psoriasis followed by a ruck of currently unnamed drugs in oncology, it may well be close to its goal. Wisely, J&J is also harnessing external partners in drug development. Janssen announced in May that it is partnering with Achillion Pharmaceutical to develop a new hepatitis C treatment, and earlier in the year the company announced an agreement with Kura Oncology to further develop tipifaranib, on top of acquiring UK virtual biopharma company XO1. —Adele Graham-King |